TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma

TIGIT/CD47 dual high expression predicts prognosis and is associated with immunotherapy response in lung squamous cell carcinoma

Abstract Background Recent studies indicated that T cell immunoreceptor with immunoglobulin and ITIM domains (TIGIT) and cluster of differentiation 47 (CD47) have emerged as new potential immunotherapy targets. However, the roles of TIGIT and CD47 in lung squamous cell carcinoma (LUSC) have not been...

Full description

Bibliographic Details
Main Authors: Yue Peng, Bin Qiu, Fengwei Tan, Jiachen Xu, Fenglong Bie, Huayu He, Lei Liu, He Tian, Guangyu Bai, Bolun Zhou, Yuan Li, Qilin Huai, Zhenlin Yang, Shugeng Gao
Format: Article
Language:English
Published: Wiley 2022-07-01
Series:Thoracic Cancer
Subjects:
CD47
immunotherapy
LUSC
NSCLC
TIGIT
Online Access:https://doi.org/10.1111/1759-7714.14478

Internet

https://doi.org/10.1111/1759-7714.14478

Similar Items